No insider purchase over the last 90 days. The latest, by 董凡, was filed 09 Mar 2022.
Jafron Biomedical Co.,Ltd.: what insiders have been doing
Jafron Biomedical Co.,Ltd. belongs to the Health Care sector. Filings by its managers are published through SSE / SZSE (CSRC). The past year has been quiet: not a single insider filing for Jafron Biomedical Co.,Ltd. The previous disclosure was published on 13 January 2023.
Looking back to 2021, when coverage begins, insiders filed 2 purchases and 4 sales.
In the same sector, recent insider purchases at Dynavox Group AB and Vetoquinol SA also feature in our signals. These figures are compiled from regulatory filings published by SSE / SZSE (CSRC). They describe what insiders did and are not a recommendation.
Since the insiders bought
- -28.2%Entry CN¥43.20 · Close at T+365 CN¥31.00
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
- 2,000 shares100.0% of flowA股XSHESZSE:173000006210994340
- 1,000 shares6.3% of flowA股XSHESZSE:173000005516556740
- 15,200 shares93.7% of flowA股XSHESZSE:173000005490811420
- 843,200 shares38.3% of flowA股XSHESZSE:173000005358173860Canonical exit: 7 Jun 2022 (T+90)
- 1,184,700 shares61.7% of flowA股XSHESZSE:173000005235904960Canonical exit: 20 Apr 2022 (T+90)
- 70,000 shares100.0% of flowA股XSHESZSE:173000004526805950
6 of 6 declarations
About Jafron Biomedical Co.,Ltd.
健帆生物 is a company focused on the health and pharmaceutical sector, specializing in the development of biological solutions. It is listed on the XSHE market.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
